{"id":"NCT02239380","sponsor":"Pfizer","briefTitle":"Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan","officialTitle":"A Multi-center, Open-label, Non-controlled Study To Evaluate The Efficacy And Safety Of Lorazepam Intravenously Administered In Subjects With Status Epilepticus Or Repetitive Status Epilepticus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11","primaryCompletion":"2016-08","completion":"2016-08","firstPosted":"2014-09-12","resultsPosted":"2019-02-18","lastUpdate":"2019-02-18"},"enrollment":26,"design":{"allocation":null,"model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Status Epilepticus"],"interventions":[{"type":"DRUG","name":"Lorazepam","otherNames":[]}],"arms":[{"label":"Lorazepam","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the efficacy, safety and pharmacokinetics of Lorazepam on Japanese patients with Status Epilepticus or Repetitive Status Eplilepticus.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved Seizure Free Interval of At Least 30 Minutes After Initial Dose (Dose 1) of Study Drug","timeFrame":"30 minutes post Dose 1","effectByArm":[{"arm":"Lorazepam","deltaMin":48,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":20,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3541002&StudyName=Lorazepam%20for%20the%20Treatment%20of%20Status%20Epilepticus%20or%20Repetitive%20Status%20Epilepticus%20in%20Japan"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":26},"commonTop":["Somnolence","Insomnia","Vomiting","Pyrexia","Pneumonia"]}}